NasdaqGM:WVEPharmaceuticals
Wave Life Sciences (WVE): Valuation Check After Positive WVE-007 Obesity Data And GlaxoSmithKline Backing
Wave Life Sciences (WVE) is back on investors radar after interim Phase 1 data for its obesity candidate WVE-007 showed healthier body composition changes along with a clean safety profile, sparking renewed interest.
See our latest analysis for Wave Life Sciences.
The excitement around WVE 007, along with Wave Life Sciences recent $350 million follow on equity raise and fresh backing from GlaxoSmithKline, has powered a 118.57% 1 month share price return and a 142.43% three year total...